Boxer Capital, LLC

Average Profitability
0.74%
Insider Buys Quantity
7
Insider Buys Sum
$112.8M
Insider Sells Quantity
9
Insider Sells Sum
$50.59M

Insider Activity of Boxer Capital, LLC

The largest purchase of all time was on 2020-07-28 and amounted to 2850000 shares of iTeos Therapeutics, Inc. for $54.15M.

The largest sale of all time was on 2022-01-03 and amounted to 515323 shares of iTeos Therapeutics, Inc. for $24.68M.

Biography of Boxer Capital, LLC

No biography is available at this moment.

2023-10-16PurchaseTango Therapeutics, Inc.
TNGX
500,000
0.5093%
$6.84$3.42M+30.29%
2023-10-13PurchaseTango Therapeutics, Inc.
TNGX
750,000
0.6778%
$7.07$5.3M+10.53%
2023-10-09SaleTango Therapeutics, Inc.
TNGX
225,000
0.2231%
$9.96$2.24M-13.88%
2023-08-23SaleiTeos Therapeutics, Inc.
ITOS
350,000
1.1785%
$16.26$5.69M-17.7%
2023-08-11PurchaseTango Therapeutics, Inc.
TNGX
475,000
0.3675%
$5.15$2.45M+11.85%
2022-01-04SaleiTeos Therapeutics, Inc.
ITOS
184,677
0.5298%
$42.77$7.9M-46.05%
2022-01-03SaleiTeos Therapeutics, Inc.
ITOS
515,323
1.4653%
$47.89$24.68M-52.16%
2021-12-17PurchaseTyra Biosciences, Inc.
TYRA
10 percent owner
250,000
0.6349%
$13.12$3.28M-28.54%
2021-09-17PurchaseTyra Biosciences, Inc.
TYRA
10 percent owner
625,000
5.4808%
$16.00$10M-43.6%
2020-09-25PurchasePMV Pharmaceuticals, Inc.
PMVP
1.9M
15.1393%
$18.00$34.2M-7.38%
2020-07-28PurchaseiTeos Therapeutics, Inc.
ITOS
10 percent owner
2.85M
12.2192%
$19.00$54.15M+45.66%
2019-03-28SaleSolid Biosciences Inc.
SLDB
10 percent owner
60,000
0.1715%
$9.53$571,800-45.05%
2019-03-27SaleSolid Biosciences Inc.
SLDB
10 percent owner
115,000
0.3335%
$9.60$1.1M-44.54%
2019-03-26SaleSolid Biosciences Inc.
SLDB
10 percent owner
275,000
0.7861%
$10.08$2.77M-47.63%
2018-11-05SaleEsperion Therapeutics, Inc.
ESPR
10 percent owner
60,000
0.2164%
$57.16$3.43M-25.99%
2018-11-02SaleEsperion Therapeutics, Inc.
ESPR
10 percent owner
40,000
0.1474%
$55.21$2.21M-21.56%
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.